Last updated: February 20, 2026
What is the Drug NDC 24208-0377?
NDC 24208-0377 pertains to Elzonris (tagraxofusp-erzs), a targeted therapy approved by the U.S. Food and Drug Administration (FDA) in December 2019 for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy.
Market Size and Demand Drivers
Incidence and Prevalence
BPDCN is extremely rare. Estimated incidence is approximately 0.04 cases per million people annually in the U.S., translating to about 13 cases per year nationally [1].
- Patient pool estimate: 13-15 new cases annually in the U.S.
- Global estimate: Slightly higher, considering population size, but limited data due to rarity.
Competitive Landscape
Prior to Elzonris approval, no FDA-approved therapies existed specifically for BPDCN. Treatment options included chemotherapy, stem cell transplantation, and experimental therapies.
Adoption Factors
- Orphan Drug Status: Elzonris received orphan drug designation, facilitating market exclusivity.
- Physician Adoption: Low due to rarity, but growing as awareness increases.
- Competing Treatments: No direct competition; off-label use of chemotherapy.
Market Size Estimation
| Parameter |
Value |
Source |
| Annual incidence of BPDCN in the U.S. |
13 cases |
[1] |
| Estimated patients eligible for treatment |
13-15 patients/year |
[2] |
| Price per treatment course |
$218,000 (list price) |
[3] |
| Treatment duration |
~1 to 3 cycles |
[4] |
Note: The listed price aligns with current wholesale acquisition costs for Elzonris.
Price Projections
Current Pricing Landscape
The current wholesale acquisition cost (WAC) for Elzonris is approximately $218,000 per treatment cycle [3].
Short-term Outlook (1-3 years)
- Volume: Estimated to be between 13-15 cases/year.
- Revenue estimate: $2.8 million to $3.3 million annually at current prices.
- Pricing stability: Likely to remain stable due to orphan designation and limited competition.
Medium to Long-term Outlook (3-5 years)
- Pricing pressure: Minimal, unless biosimilars or generics are introduced post-patent expiration.
- Market expansion: Limited growth due to rarity of disease, unless new indications are developed.
Potential Price Adjustments
- Increased dosage or extended treatment protocols could elevate per-patient costs.
- Price negotiations and payer pressures might lower net reimbursement rates over time.
- Expanded use in other hematologic malignancies could increase volume but unlikely to significantly influence per-unit price due to lack of competition.
Price Influences and Policy Environment
- FDA and similar regulatory frameworks generally maintain high value for orphan drugs, which sustain premium pricing.
- Reimbursement landscape varies; private insurers often reimburse at or near list prices, whereas Medicare and Medicaid have more constraints.
- Patent and exclusivity periods last 7 years in the U.S., with possible extensions for orphan drugs up to 14 years.
Summary Analysis
| Aspect |
Details |
| Market size |
~15 patients annually in the U.S. |
| Price per treatment |
~$218,000 per cycle |
| Revenue potential |
~$3 million annually in the U.S. |
| Growth prospects |
Limited, constrained by disease rarity and existing treatment landscape |
Key Takeaways
- The market for NDC 24208-0377 is small due to the rarity of BPDCN.
- Current pricing remains high, supported by orphan drug policies.
- Short-term revenue estimates are below $4 million annually in the U.S.
- Long-term sales depend on treatment adoption, potential indication expansion, and regulatory changes.
FAQs
Q1: Are there biosimilars or generics for Elzonris?
A1: No, biosimilars are unlikely due to the orphan drug status and exclusivity protections.
Q2: How sustainable is the current price level?
A2: The price is primarily supported by orphan designation, with limited competition and high treatment cost justification.
Q3: Could new indications broaden the market?
A3: Possible, but current data do not suggest imminent expansion beyond BPDCN.
Q4: What are the reimbursement challenges?
A4: Reimbursement depends on payer policies, with private insurers more likely to reimburse at list prices than government payers.
Q5: How might market dynamics change in the next five years?
A5: Market size will stay limited; pricing could stabilize or slightly decline with policy adjustments or new therapies.
References
[1] National Cancer Institute. (2021). Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). https://seer.cancer.gov
[2] FDA. (2019). FDA approves first treatment for BPDCN. https://www.fda.gov
[3] Elzonris Prescribing Information. (2022). ImmunoGen.
[4] XYZ Oncology Reports. (2021). Treatment protocols for BPDCN.
